Truist analyst Srikripa Devarakonda raised the firm’s price target on Eli Lilly (LLY) to $1,182 from $1,038 and keeps a Buy rating on the shares. The firm is positive on the stock based on the recently announced White House deal that provides reimbursement for weight loss medications to Medicare patients, the analyst tells investors in a research note. Truist adds that it expects orforglipron to be on the market in the first half of 2026 and believes that the competitive profiles of Zebpound and orforglipron will continue to support Eli Lilly leadership in the obesity landscape.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly plans to open Gateway Labs site in Philadelphia
- LifeMD price target lowered to $8 from $12 at KeyBanc
- Eli Lilly price target raised to $1,150 from $1,050 at JPMorgan
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Eli Lilly Stock (LLY) Falls as Rival Novo Nordisk Cuts Weight-Loss Drug Prices